The RNA Transcript, May 2, 2022 |
|
|
|
Introducing the RNA 2022 Content Library
The RNA Society is trying something new this year! The RNA 2022 Content Library - including Keynote Lectures, Awardee talks, and each of the 200 oral and 600 poster presentations – will be made available on-line for RNA researchers wanting to take in all the cutting-edge science from RNA 2022.
|
|
The RNA 2022 Content Library will include pre-recorded talks and pdf poster files from all presenters at RNA 2022 and will be viewable on-demand from June 7th – June 30th! For more information, visit RNA Digital Content Library.
RNA Society Inclusion Initiative: RNA researchers who might not otherwise have the financial resources to subscribe to this on-line scientific content are encouraged to check their eligibility – which waives the subscription fee for scientists who are first-time RNA Society meeting attendees (in-person or on-line) or who affiliate with a broad group of under-represented scientists. No application process – simply answer the questions, attest to your qualifications and receive a fee waiver.
|
|
After COVID-19, mRNA vaccines could treat flu, HIV and even cancer
|
|
Vaccines to protect against severe illness and death from COVID-19 started as the key to a return to normal, but they could wind up unlocking much more for the future of health care. The mRNA vaccine technology used by Pfizer/BioNTech and Moderna for their respective coronavirus vaccines has been heavily touted by doctors and public health officials as a modern miracle of science and a means to revolutionize vaccine development. Read more
|
|
“It’s hard to overestimate the impact this will have on human health,” said Nils Walter, a professor of biological chemistry at the University of Michigan who has studied mRNA for about 30 years. “It’s like introducing the iPhone when everyone had a flip phone.”
|
|
The breakthrough science of mRNA medicine
The secret behind medicine that uses mRNA is that it "teaches" our bodies how to fight diseases on our own, leading to groundbreaking treatments for COVID-19 and, potentially one day, cancer, the flu and other ailments that have haunted humanity for millennia.
RNA researcher Melissa J. Moore -- Moderna's chief scientific officer and one of the many people responsible for the rapid creation and deployment of their COVID-19 vaccine -- takes us down to the molecular level, unraveling how mRNA helps our bodies' proteins maintain health, prevent disease, and correct errors in our genetic code.
"We have entered an entirely new era of medicine," Moore says.
|
|
Keystone Symposia on Molecular Cellular BIology |
|
|
|
Small Regulatory RNAs: From Bench to Bedside
Frank Slack, Jörg Vogel, Ivan Martinez, Karyn Schmidt
May 1-4, 2022
Santa Fe, New Mexico
|
|
U-M Oral Dissertation Defense |
|
|
|
Investigation of Developmental Disorders: Genetic Discovery and Functional Validation
Monday, May 2, 2022
3:00 - 4:00 AM
West Lecture Hall
|
|
U-M RNA Student Postdoc Council | Pub Science Night |
|
|
|
RNA Trivia Night
Join the RNA Student Postdoc Council in the Trivia Night - Loads of fun with Teams, Prizes, Drinks and more!
Tuesday, May 3, 2022
7:00 pm - 9:00 pm
Conor O’Neil’s (318 S Main St)
|
|
----Wednesday, May 4, 2022
----4:00 pm - 5:00 pm
|
|
Developmentally regulated RNA isoforms expression programs revealed by scRNA-seq
Dissecting post-transcriptional circuits in immune responses
|
|
|
ISTAART Alzheimer's Association |
|
|
|
Vascular Cognitive Disorders PIA: New advances in biomedical sciences transferable to VCID research?
Nils Walter, Co-Director, U-M Center for RNA Biomedicine
Friday, May 6, 2022
4:00 pm - 5:00 pm
|
|
U-M RNA Innovation Seminar |
|
|
|
Unexpected determinants of neuronal identity and properties: the curious cases of PTBP1, PTBP2, and neuronal splicing
Monday, May 9, 2022
4:00 pm - 5:00 pm
|
|
|
|
Viral Pathogens: Us vs. Them
Friday, May 13, 2022
8:45 am - 4:10 pm
Kahn Auditorium, BSRB
|
|
|
|
Catalyzing translational research efforts by supporting preclinical and commercial clinical development |
|
Innovation Partnerships at the University of Michigan manages Great Lakes Discovery, a ten-year collaboration with Deerfield Management Company, L.P to fund U-M drug discovery from early-stage research to clinical development.
-
Deerfield has committed up to $130 million over the next decade to invest in biomedical research at U-M with the aim of developing potentially life-saving drugs and disease treatments.
-
Projects selected by Great Lakes Discovery will be provided funding and operational support through a development plan aimed at achieving Investigational New Drug (IND) readiness.
GET STARTED WITH A CONSULTATION There is no open Request for Proposal (RFP) - the first step for an interested researcher is to schedule a consultation with the program’s Scientific Collaboration Manager Dr. Seohee You (shyou@umich.edu).
|
|
|
|
Several RNA-based biotech companies are looking to hire good scientists!
|
|
Confluence Therapeutics is developing a novel platform of oligonucleotide therapeutics for diseases of the CNS and other therapeutic areas with significant unmet need. Three positions open, click for more detail:
|
|
Appletree Partner Research and Development Labs (ATP R&D Labs) is a biotech in Branford, CT developing drugs for oncology and neuroscience. We are funded by Appletree Partners, a leading Life Sciences Venture Capital firm. Two positions open, click for more detail:
|
|
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Postdoc position open, click below for more detail:
|
|
|
|
Our members' publications are available through Altmetrics. Queries are currently available: CRISPR, microRNA, molecule, RNA, RNA therapeutics, transcriptome, and translation. Below are recent highlights.
|
|
RNA sequencing reveals perivascular adipose tissue plasticity in response to angiotensin II, Z. Wang, H. Lu, M. Garcia-Barrio, Y. Guo, J. Zhang, Y. E. Chen, L. Chang (2022) Pharmacological Research 178. 10.1016/j.phrs.2022.106183
Keywords: RNA sequencing, Perivascular adipose tissue, Angiotensin II, MitoNEET
|
|
Joint dimension reduction and clustering analysis of single-cell RNA-seq and spatial transcriptomics data, W. Liu, X. Liao, Y. Yang, H. Lin, J. Yeong, X. Zhou, X. Shi, J. Liu (2022) Nucleic Acids Research . 10.1093/nar/gkac219
DR-SC outperforms existing clustering and spatial clustering methods: it extracts more biologically relevant features than conventional dimension reduction methods, improves clustering performance, and offers improved trajectory inference and visualization for downstream trajectory inference analyses.
|
|
|
|
|
|
|
